… The aim of the present study was to conduct a comprehensive analysis of safety in the …
comprehensive analysis of safety data from four clinical trials evaluating pirfenidone in patients …

… CI, 1.09-21.83) were higher with pirfenidone. The quality of the … , Assessment, Development
and Evaluation criteria, depending on the outcome. Conclusions: Pirfenidone use in patients …

… and tolerability of pirfenidone, we performed a comprehensive analysis of safety outcomes
in the integrated population from five clinical trials evaluating pirfenidone in patients with IPF, …

… patients with pirfenidone reduces lung function decline, improves progression-free survival
and significantly reduces the risk of all-cause mortality at 1 year. Pirfenidone … some patients …

… This real study assessed the efficacy and safety of different plasma concentrations … pirfenidone
in patients with IPF. The study included 99 patients with IPF orally treated with pirfenidone …

… Pirfenidone had a manageable tolerability profile in all three studies. Gastrointestinal and …
with pirfenidone. In conclusion, oral pirfenidone is a valuable agent for use in patients with IPF. …

… of responsiveness and adverse effects of pirfenidone in IPF patients treated in our institute.
… A comprehensive assessment revealed that 6 cases improved 3–6 months after pirfenidone …

… pirfenidone treatment of patients with idiopathic pulmonary fibrosis (IPF) are limited. This study
assessed the effectiveness of pirfenidone in … of pirfenidone in key patient subgroups in the …

… with Systemic Sclerosis-Related Interstitial Lung Disease) was designed to assess the safety
and tolerability of pirfenidone in patients with SSc-ILD at the same therapeutic dose used in …

… A total of 307 patients receiving pirfenidone were identified for analysis. The mean age was
… diagnosis to start of pirfenidone treatment was 6 (2–23) months. Patients were followed on …